UBS Group Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price
UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a report on Thursday...